BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 20444936)

  • 1. Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor.
    Tian L; Gao J; Hao J; Zhang Y; Yi H; O'Brien TD; Sorenson R; Luo J; Guo Z
    Endocrinology; 2010 Jul; 151(7):3049-60. PubMed ID: 20444936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulating CD4+CD25+FOXP3+ regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy.
    Tian B; Hao J; Zhang Y; Tian L; Yi H; O'Brien TD; Sutherland DE; Hering BJ; Guo Z
    Transplantation; 2009 Jan; 87(2):198-206. PubMed ID: 19155973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dreams for type 1 diabetes: shutting off autoimmunity and stimulating beta-cell regeneration.
    Weir GC; Bonner-Weir S
    Endocrinology; 2010 Jul; 151(7):2971-3. PubMed ID: 20570953
    [No Abstract]   [Full Text] [Related]  

  • 4. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
    Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice.
    Reimer MK; Holst JJ; Ahrén B
    Eur J Endocrinol; 2002 May; 146(5):717-27. PubMed ID: 11980629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cells with TGF-beta1 differentiate naive CD4+CD25- T cells into islet-protective Foxp3+ regulatory T cells.
    Luo X; Tarbell KV; Yang H; Pothoven K; Bailey SL; Ding R; Steinman RM; Suthanthiran M
    Proc Natl Acad Sci U S A; 2007 Feb; 104(8):2821-6. PubMed ID: 17307871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
    Akarte AS; Srinivasan BP; Gandhi S
    Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes.
    Cabrera SM; Colvin SC; Tersey SA; Maier B; Nadler JL; Mirmira RG
    Clin Exp Immunol; 2013 Jun; 172(3):375-82. PubMed ID: 23600825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice.
    Tarbell KV; Petit L; Zuo X; Toy P; Luo X; Mqadmi A; Yang H; Suthanthiran M; Mojsov S; Steinman RM
    J Exp Med; 2007 Jan; 204(1):191-201. PubMed ID: 17210729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surge in regulatory T cells does not prevent onset of hyperglycemia in NOD mice: immune profiles do not correlate with disease severity.
    Kaminitz A; Mizrahi K; Askenasy N
    Autoimmunity; 2014 Mar; 47(2):105-12. PubMed ID: 24328490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor induces β-cell neogenesis from adult human pancreatic duct cells implanted in immunodeficient mice.
    Suarez-Pinzon WL; Rabinovitch A
    Cell Transplant; 2011; 20(9):1343-9. PubMed ID: 21396168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulating β-cell regeneration by combining a GPR119 agonist with a DPP-IV inhibitor.
    Ansarullah ; Lu Y; Holstein M; DeRuyter B; Rabinovitch A; Guo Z
    PLoS One; 2013; 8(1):e53345. PubMed ID: 23382843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV.
    Hughes TE; Mone MD; Russell ME; Weldon SC; Villhauer EB
    Biochemistry; 1999 Sep; 38(36):11597-603. PubMed ID: 10512614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining MK626, a novel DPP-4 inhibitor, and low-dose monoclonal CD3 antibody for stable remission of new-onset diabetes in mice.
    Ding L; Gysemans CA; Stangé G; Heremans Y; Yuchi Y; Takiishi T; Korf H; Chintinne M; Carr RD; Heimberg H; Pipeleers D; Mathieu C
    PLoS One; 2014; 9(9):e107935. PubMed ID: 25268801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dipeptidyl peptidase IV inhibitor NVP-DPP728 reduces plasma glucagon concentration in cats.
    Furrer D; Kaufmann K; Tschuor F; Reusch CE; Lutz TA
    Vet J; 2010 Mar; 183(3):355-7. PubMed ID: 19128990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes.
    Akarte AS; Srinivasan BP; Gandhi S
    J Diabetes Complications; 2012; 26(4):266-74. PubMed ID: 22626875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of residual beta cells and islet autoimmunity during increasing duration of diabetes in NOD mice and experimental approaches toward reversing new-onset disease with bioactive peptides.
    Reddy S; Cheung CC; Chai RC; Rodrigues JA
    Ann N Y Acad Sci; 2008 Dec; 1150():171-6. PubMed ID: 19120289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis.
    Cho JM; Jang HW; Cheon H; Jeong YT; Kim DH; Lim YM; Choi SH; Yang EK; Shin CY; Son MH; Kim SH; Kim HJ; Lee MS
    Diabetes Res Clin Pract; 2011 Jan; 91(1):72-9. PubMed ID: 21093089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
    Ishibashi K; Hara A; Fujitani Y; Uchida T; Komiya K; Tamaki M; Abe H; Ogihara T; Kanazawa A; Kawamori R; Watada H
    Biochem Biophys Res Commun; 2013 Nov; 440(4):570-5. PubMed ID: 24103756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 16,17-Dihydro-17b-hydroxy isomitraphylline alkaloid as an inhibitor of DPP-IV, and its effect on incretin hormone and β-cell proliferation in diabetic rat.
    Shukla A; Srinivasan BP
    Eur J Pharm Sci; 2012 Sep; 47(2):512-9. PubMed ID: 22820565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.